dc.creatorCamargo-Ayala, Lorena
dc.creatorBedoya, Mauricio
dc.creatorPrent-Peñaloza, Luis
dc.creatorPolo-Cuadrado, Efraín
dc.creatorOsorio, Edison
dc.creatorBrito, Iván
dc.creatorDelgado, Gerzon E.
dc.creatorGonzález, Wendy
dc.creatorGutierrez, Margarita
dc.date2024-04-08T16:46:31Z
dc.date2024-04-08T16:46:31Z
dc.date2024
dc.date.accessioned2024-05-02T20:32:21Z
dc.date.available2024-05-02T20:32:21Z
dc.identifierhttp://repositorio.ucm.cl/handle/ucm/5293
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9275476
dc.descriptionThe increase in and concern about neurodegenerative diseases continue to grow in an increasingly long-lived world population. Therefore, the search for new drugs continues to be a priority for medicinal chemistry. We present here the synthesis of a series of compounds with acetamide nuclei. Their structures were established using UV-Visible, NMR, HRMS and IR techniques. Furthermore, we report the crystal structures that were obtained from compounds 5a–5d by X-ray diffraction. The compounds were evaluated as potential inhibitors of the monoxidase enzymes; A (MAO-A) and B (MAO-B), and cholinesterases; acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) through in silico studies using the induced fit docking (IFD) method and binding free energy (ΔGbind) calculations by the MMGBSA method. Interestingly, compounds 5b, 5c and 5d showed much better ΔGbind than the reference drug Zonisamide. Compound 5c is the best in the series, which indicates a potential selective affinity of our compounds against MAO-B, which could be a promising finding in the search for new drugs for Parkinson's disease treatment. The acetamide crystal exhibits moderate NLO properties suggesting that it could be considered a potential candidate for application in nonlinear optical devices.
dc.languageen
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.sourceRSC Advances, 14(8), 5222-5233
dc.titleCrystal structure, quantum chemical insights, and molecular docking studies of Naryl-2-(N-disubstituted) acetamide compounds: potential inhibitors for neurodegenerative enzymes
dc.typeArticle


Este ítem pertenece a la siguiente institución